Ilyang Pharmaceutical Co.,Ltd Statistics

Total Valuation

Ilyang Pharmaceutical Co.,Ltd has a market cap or net worth of KRW 197.43 billion. The enterprise value is 332.96 billion.

Market Cap	197.43B
Enterprise Value	332.96B

Important Dates

The next estimated earnings date is Friday, February 14, 2025.

Earnings Date	Feb 14, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

Ilyang Pharmaceutical Co.,Ltd has 18.01 million shares outstanding. The number of shares has decreased by -0.42% in one year.

Current Share Class	n/a
Shares Outstanding	18.01M
Shares Change (YoY)	-0.42%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	28.39%
Owned by Institutions (%)	3.89%
Float	12.90M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.54
PB Ratio	0.85
P/TBV Ratio	0.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.35, with an EV/FCF ratio of -13.82.

EV / Earnings	-451.37
EV / Sales	0.91
EV / EBITDA	18.35
EV / EBIT	55.52
EV / FCF	-13.82

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 0.45.

Current Ratio	0.89
Quick Ratio	0.51
Debt / Equity	0.45
Debt / EBITDA	3.74
Debt / FCF	-5.07
Interest Coverage	6.05

Financial Efficiency

Return on equity (ROE) is 0.80% and return on invested capital (ROIC) is 3.39%.

Return on Equity (ROE)	0.80%
Return on Assets (ROA)	2.51%
Return on Capital (ROIC)	3.39%
Revenue Per Employee	572.31M
Profits Per Employee	-1.16M
Employee Count	637
Asset Turnover	0.71
Inventory Turnover	2.21

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.75% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-28.75%
50-Day Moving Average	11,764.00
200-Day Moving Average	13,206.85
Relative Strength Index (RSI)	46.12
Average Volume (20 Days)	32,244

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ilyang Pharmaceutical Co.,Ltd had revenue of KRW 364.56 billion and -737.67 million in losses. Loss per share was -44.30.

Revenue	364.56B
Gross Profit	196.11B
Operating Income	20.55B
Pretax Income	2.05B
Net Income	-737.67M
EBITDA	32.71B
EBIT	20.55B
Loss Per Share	-44.30

Full Income Statement

Balance Sheet

The company has 26.86 billion in cash and 122.24 billion in debt, giving a net cash position of -95.38 billion or -5,294.82 per share.

Cash & Cash Equivalents	26.86B
Total Debt	122.24B
Net Cash	-95.38B
Net Cash Per Share	-5,294.82
Equity (Book Value)	271.37B
Book Value Per Share	12,864.23
Working Capital	-24.33B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.27 billion and capital expenditures -26.37 billion, giving a free cash flow of -24.10 billion.

Operating Cash Flow	2.27B
Capital Expenditures	-26.37B
Free Cash Flow	-24.10B
FCF Per Share	-1,337.87

Full Cash Flow Statement

Margins

Gross margin is 53.79%, with operating and profit margins of 5.64% and -0.22%.

Gross Margin	53.79%
Operating Margin	5.64%
Pretax Margin	0.56%
Profit Margin	-0.22%
EBITDA Margin	8.97%
EBIT Margin	5.64%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.37%.

Dividend Per Share	150.00
Dividend Yield	1.37%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.42%
Shareholder Yield	1.79%
Earnings Yield	-0.40%
FCF Yield	-12.21%

Dividend Details

Stock Splits

The last stock split was on June 26, 2006. It was a forward split with a ratio of 2.

Last Split Date	Jun 26, 2006
Split Type	Forward
Split Ratio	2

Scores

Ilyang Pharmaceutical Co.,Ltd has an Altman Z-Score of 1.49. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.49
Piotroski F-Score	n/a